When a 99th-percentile longevity-optimized human (top 1% biological Pace of Aging + early frontier therapy access) crosses ≥1.0 year of healthy life expectancy gained per calendar year.
Ages 7.9 bio-months per 12 calendar months — banking +124 days/yr of healthy runway today.
Ages 10.1 bio-months per 12 calendar months — banking +59 days/yr of healthy runway today.
Ages 12.0 bio-months per 12 calendar months — standard population actuarial curve tracked by Metaculus #6592.
Metaculus #6592 (national LEV) held at Nov 2053 while Manifold 2036/2040 frontier LEV markets firmed (+1.5% WoW), pulling our 99th-percentile LEV aggregate 26 days closer to October 2036.
Translational geroscience teams highlighted that standardized surrogate methylation clocks (DunedinPACE, PCGrimAge across 51 human trials) and immune-mediated senolytics are compressing Phase 2 efficacy readouts from multi-year survival studies to 6-month biomarker windows.
Five peer-reviewed breakthroughs converged on intracellular maintenance: oral AEP inhibitor #11a preserved NAMPT to extend aged mouse lifespan 17% (24m to 28m); spider-silk nanovaccine CK5-GC-NV cleared Gpnmb+ senescent cells (HR = 0.28); astrocyte FGF13 and neuronal PLA2G2F reversed glial lipid toxicity and systemic IL-6; and TranslAGE benchmarked 16 epigenetic clocks across 51 human clinical trials.
Blocking asparaginyl endopeptidase (AEP) prevents proteolytic cleavage of NAMPT at N164/N335, restoring tissue NAD+ and SIRT1 deacetylation and extending average lifespan in 18-month-old mice by 17%.
Dual STING + TLR9 spider-silk nanovaccine rejuvenated aged dendritic cells and primed CD8+ T cells to clear Gpnmb+ senescent cells, extending median survival from 79.0 to 91.0 weeks (72% lower mortality hazard).
Prefrontal cortex astrocyte FGF13 restoration reactivated lysosomal autophagy and reduced circulating inflammatory cytokines and peripheral organ senescence in 26-month-old mice.
Replacing neuronal PLA2G2F hydrolyzed peroxidized phospholipids and cholesterol esters in human iPSC-derived microglia, restoring Aβ phagocytosis and spatial memory.
Harmonized evaluation of 16 epigenetic clocks and 94 DNAm biomarkers across 51 human longitudinal trials confirmed DunedinPACE and PCGrimAge reliably detect biological age deceleration within months.
Modeled on levlhealth.com/LEVTrajectory: compares the Status Quo (50th Pct dashed orange) against the 80th Percentile Health Optimizer (solid cyan) and 99th Percentile Protocol Frontier (solid green + Cone of Uncertainty).
Single epigenetic clock readings (e.g., 0.48 DunedinPACE) can overstate systemic organ rejuvenation. This graphic shrinks raw leaderboard extremes by 35% toward multi-system physiological markers (VO2 max, HRV, ApoB, glycan/proteomic clocks) aligned with LEVL Trajectory.
| Platform & Weight | Question & Resolution Criteria | Raw Crowd Metric | 99th-Pct Human LEV | 80th / 50th Pct | Cohort Translation Rationale |
|---|---|---|---|---|---|
MetaculusWeight: 34% • 480+ forecasters • 1,200+ predictions | When will a country reach longevity escape velocity, i.e. sustained increase of life expectancy of at least 1? First calendar year in which any country's period life expectancy increases by >= 1.0 year/year over a sustained multi-year window. | Median: Nov 2053 (Q1: Oct 2038 • Q3: 2096) | Mar 2038 (2038.2) | 80th: 2043.6 50th: 2053.8 | National period life expectancy lags 99th-percentile frontier individuals by ~15.6 yrs due to population demographic inertia, regulatory reimbursement lag, and the 34% lower baseline biological damage rate (PoA ~0.66 vs 1.00) in top-1% protocol adherents. Aligns with Metaculus Q1 (2038.8). |
Manifold MarketsWeight: 22% • High-liquidity binary market | Life Extension Velocity (LEV) - for every year we survive, we gain an extra year - by 2036? Resolves YES if scientific/medical consensus or verified clinical survival metrics show >= 1 year of life expectancy gained per calendar year by end of 2036. | 34% probability by 2036 | Oct 2037 (2037.8) | 80th: 2042.2 50th: 2050.5 | Fitting a Weibull cumulative hazard curve anchored at 11% (2030) and 34% (2036) places the 50% threshold for frontier human LEV at ~2037.8 and general population rollout at ~2050.5. |
Foresight / ManifoldWeight: 18% • Foresight Institute benchmark market | Will one person currently alive reach longevity escape velocity? (Foresight Vision Weekend) Resolves YES if at least one human alive today reaches actuarial/biological escape velocity without reliance on cryonics suspension. | 49% probability (48%–51% range) | Nov 2036 (2036.9) | 80th: 2041.8 50th: 2052 | For top-1% biologically optimized cohorts alive today to bridge into full regenerative escape velocity before late-life frailty, the initial frontier LEV window implied by a ~49% survival-to-LEV odds centers at ~2036.9. |
Manifold MarketsWeight: 14% • Active binary market | Longevity escape velocity before 2030? Scientific consensus, major journal publication, or regulatory recognition that human LEV is achieved prior to Jan 1, 2030. | 11% probability before 2030 | May 2037 (2037.4) | 80th: 2042 50th: 2051.4 | Establishes the early-tail P10 bound (~2030.2): traders assign an 11% chance that AI-accelerated therapeutics + extreme protocol optimization cross LEV this decade, with median frontier crossing in the late 2030s. |
Manifold MarketsWeight: 12% • Composite demographic markets | General anti-aging treatments available to the public by 2040 & age-cohort split (30yo vs 80yo) Broad commercial/clinical availability of validated age-reversing therapeutics by 2040 (38%) + 64% probability that 30yo cohorts reach LEV earlier than 80yo cohorts. | 38% Public by 2040 • 64% Younger/Low-Damage First | Aug 2036 (2036.6) | 80th: 2041.9 50th: 2051.8 | 38% mass-public availability by 2040 implies a median mass rollout around ~2043–2045 and 99th-percentile early-access / clinical-protocol intercept ~6–7 years earlier (~2036.6). |
| Expert & Affiliation | Stated Timeline & Confidence | 99th-Pct Point (Range) | 80th / 50th Pct | Primary Mechanism & Citation |
|---|---|---|---|---|
Aubrey de Grey, PhD President, LEV Foundation • Coiner of 'Longevity Escape Velocity' Weight: 16% | 2036–2038 (50% probability mark) Estimates ~50% chance of reaching human LEV by mid-to-late 2030s if Robust Mouse Rejuvenation & combination trials stay funded. | 2037 Range: 2034–2042 | 80th: 2041.5 50th: 2049 | Comprehensive damage repair across 7 SENS pillars: multi-modal senolytics, extracellular matrix crosslink breakers, mitochondrial allotopic expression, and stem cell replenishment. LEV Foundation Roadmap & Robust Mouse Rejuvenation Updates (2025) |
Dario Amodei, PhD CEO & Co-Founder, Anthropic • PhD Biophysics (Princeton) Weight: 14% | 2033–2036 ('Compressed 21st Century') Projects AI compressing 50–100 years of biological research into 5–10 years, doubling human lifespan to ~150 years and enabling escape velocity for living cohorts. | 2034.5 Range: 2032–2038 | 80th: 2039.5 50th: 2047 | AI-accelerated biological discovery: virtual cell modeling, automated wet-lab hypothesis loops, precision clinical trial design, and multi-target genetic/epigenetic interventions. Machines of Loving Grace: How AI Could Transform the World for the Better (2024) |
George Church, PhD Professor of Genetics, Harvard Medical School & MIT • Wyss Institute Weight: 12% | Mid-to-Late 2030s (~2035–2040) Notes frontier cohorts could cross early borders of LEV within a decade via multiplex gene therapy and combinatorial cellular reprogramming. | 2037.5 Range: 2034–2043 | 80th: 2042.5 50th: 2050 | Multiplex AAV & CRISPR gene therapies (simultaneously targeting TGF-β, FGF21, αKlotho, telomerase) plus programmable epigenetic editing. Harvard Wyss Institute & Rejuvenate Bio Combinatorial Gene Therapy Research (2025) |
Ray Kurzweil Principal Researcher & AI Visionary, Google • Author, The Singularity Is Nearer Weight: 11% | 2029–2032 (99th Percentile by ~2030) Explicitly distinguishes diligent, well-resourced early adopters (reaching LEV ~2029–2030) from broader population rollout (~2032+). | 2030.5 Range: 2029–2033 | 80th: 2035 50th: 2042 | Bridge 1 (current precision protocols) -> Bridge 2 (AI-simulated biology & mRNA/gene reprogramming in late 2020s/early 2030s) -> Bridge 3 (medical nanorobotics). The Singularity Is Nearer: When We Merge with AI (2024) |
David Sinclair, PhD Professor of Genetics, Harvard Medical School • Author, Lifespan Weight: 10% | Late 2030s (~2036–2040) Following primate optic nerve restoration and early human partial-reprogramming trials, projects systemic age-resetting therapeutics scaling in the late 2030s. | 2038 Range: 2035–2043 | 80th: 2043 50th: 2051 | Information Theory of Aging: partial epigenetic reprogramming using inducible OSK (Oct4, Sox2, Klf4) Yamanaka factors & chemical reprogramming cocktails. Harvard Glenn Center for Biology of Aging Research / Life Biosciences (2025) |
Bryan Johnson Founder, Project Blueprint & Rejuvenation Olympics Weight: 10% | Mid 2030s (~2034–2038 Bridge Intercept) Demonstrated DunedinPACE scores of 0.48–0.64; argues that cutting personal biological aging velocity by ~35–45% halves the biotech hurdle needed to hit LEV. | 2035.8 Range: 2033–2039.5 | 80th: 2041.5 50th: 2052 | Continuous 100+ organ biomarker quantification, caloric/circadian precision, exercise/VO2 max optimization, and stacked regenerative therapies (plasma, follistatin, senolytics). Rejuvenation Olympics & Project Blueprint Longitudinal Biomarker Ledger (2026) |
Peter Diamandis, MD Founder, XPRIZE Healthspan ($101M) & Fountain Life Weight: 8% | 2030–2034 (Frontier Early Adopters) XPRIZE Healthspan targets a verified 10–20 year functional reversal in muscle, cognition, and immunity by 2030 as the direct catalyst for 99th-percentile LEV. | 2032.2 Range: 2030–2035.5 | 80th: 2037.5 50th: 2045 | AI multimodal early detection (full-body MRI + liquid biopsy) + therapeutic plasma exchange, NK/stem cell infusions, and XPRIZE Healthspan clinical trial winners. XPRIZE Healthspan & Longevity Mindset Roadmap (2025) |
Demis Hassabis & Sam Altman (AI-Bio Labs) Isomorphic Labs / DeepMind (Nobel '24) & Retro Biosciences ($1B+) Weight: 8% | 2035–2040 (+10 Healthy Years Bridge -> LEV) Retro Biosciences targets adding +10 healthy human years in the 2030s; Isomorphic Labs targets AI-designed clinical drug candidates compressing preclinical timelines by 10x. | 2037.8 Range: 2035–2042 | 80th: 2042.8 50th: 2051 | AlphaFold 3 rational molecular design + Retro's 3-pillar focus: autophagy enhancement, hematopoietic/microglia rejuvenation, and partial cellular reprogramming. Retro Biosciences & Isomorphic Labs Translational Roadmaps (2025) |
José Luis Cordeiro, PhD MIT Engineer • Fellow, World Academy of Art & Science • Author, The Death of Death Weight: 5% | 2029–2030 (LEV Bridge) • 2045 (Full Rejuvenation) Predicts initial escape velocity bridge by 2029–2030 for proactive individuals, culminating in full clinical biological age reversal by 2045. | 2030.5 Range: 2029–2035 | 80th: 2036.5 50th: 2045 | Exponential biotechnology convergence: induced pluripotent stem cells, telomere extension, organ bioprinting, and gene editing. The Death of Death: The Scientific Possibility of Physical Immortality (2023) |
Celine Halioua & Laura Deming (Biotech Realists) CEO, Loyal • Founder, The Longevity Fund (Translational Geroscience) Weight: 6% | 2042–2050 (FDA-Cleared Systemic Rollout) Emphasizes clinical trial safety windows, biodistribution hurdles for in vivo reprogramming, and stepwise FDA validation before human LEV is achieved. | 2045 Range: 2040–2052 | 80th: 2051 50th: 2060 | Validated preventive metabolic & senolytic drugs clearing FDA proxy endpoints first, followed by multi-decade translational scaling of systemic rejuvenation. Translational Geroscience & Regulatory Pathways for Aging Therapeutics (2025) |
Email newsletters strip <script> and <iframe> tags — so we built a live server-rendered SVG image endpoint (/api/embed/lev-card) for Substack, Beehiiv, ConvertKit, and Ghost emails, plus an interactive <iframe> & 1-line <script> widget for websites.
<!-- Dynamic LEV 99th-Percentile & Pace of Aging Graphic (Auto-updates conservatively; works in Substack, Beehiiv, ConvertKit, Ghost) -->
<figure style="margin: 24px 0; text-align: center;">
<a href="https://www.levlhealth.com/LEVTrajectory/" target="_blank" rel="noopener noreferrer" style="display: inline-block; text-decoration: none;">
<img
src="https://futuregraph-beta.vercel.app/api/embed/lev-card?theme=light&variant=full&age=35&mode=conservative"
alt="99th Percentile Human LEV Date (July 2036) and Dynamic Pace of Aging: 99th Percentile = 0.66 yr/yr, 80th Percentile = 0.84 yr/yr"
width="100%"
style="max-width: 720px; height: auto; border-radius: 14px; border: 1px solid #cbd5e1; display: block;"
/>
</a>
<figcaption style="margin-top: 8px; font-family: system-ui, -apple-system, sans-serif; font-size: 13px; color: #64748b;">
Live Conservative Aggregate: <strong>99th-Pct LEV = July 2036 (2036.5)</strong> • 99th-Pct Pace of Aging: <strong>0.66 yr/yr</strong> • 80th-Pct: <strong>0.84 yr/yr</strong>. Model tied to <a href="https://www.levlhealth.com/LEVTrajectory/" target="_blank" rel="noopener noreferrer" style="color: #047857; font-weight: 600;">levlhealth.com/LEVTrajectory</a>.
</figcaption>
</figure>[](https://www.levlhealth.com/LEVTrajectory/)
*Live Conservative Aggregate: **99th-Percentile Human LEV = July 2036 (2036.5)** (IQR: Feb 2033–Sep 2040) | Current Pace of Aging: **99th Pct = 0.66 bio-yr/yr**, **80th Pct = 0.84 bio-yr/yr** — [Explore your personal trajectory at levlhealth.com/LEVTrajectory](https://www.levlhealth.com/LEVTrajectory/)*<!-- Email-Safe Inline Table + Live Dynamic Chart Card for Newsletters -->
<table role="presentation" width="100%" cellpadding="0" cellspacing="0" style="max-width: 680px; margin: 20px auto; border: 1px solid #cbd5e1; border-radius: 14px; overflow: hidden; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; background-color: #ffffff; color: #0f172a;">
<tr>
<td style="padding: 18px 20px; background-color: #0f172a; color: #f8fafc;">
<div style="font-size: 11px; font-weight: 800; letter-spacing: 1.2px; color: #10b981; text-transform: uppercase;">Longevity Escape Velocity (LEV) & Pace of Aging Tracker</div>
<div style="font-size: 20px; font-weight: 800; margin-top: 4px;">99th-Percentile Human LEV: <span style="color: #10b981;">July 2036 (2036.5)</span></div>
<div style="font-size: 12px; color: #94a3b8; margin-top: 4px;">Aggregating Metaculus #6592, Manifold Markets, 10 Notable Experts & LEVL Health Trajectory</div>
</td>
</tr>
<tr>
<td style="padding: 0;">
<a href="https://www.levlhealth.com/LEVTrajectory/" target="_blank" rel="noopener noreferrer">
<img src="https://futuregraph-beta.vercel.app/api/embed/lev-card?theme=light&variant=full&age=35&mode=conservative" alt="LEV Trajectory & Pace of Aging Chart" width="680" style="width: 100%; max-width: 680px; height: auto; display: block; border: 0;" />
</a>
</td>
</tr>
<tr>
<td style="padding: 14px 20px; background-color: #f8fafc; border-top: 1px solid #e2e8f0; font-size: 13px; color: #334155;">
<strong>Current Pace of Aging (Conservative Update):</strong> 99th Pct = <strong>0.66 yr/yr</strong> (+124d/yr banked) • 80th Pct = <strong>0.84 yr/yr</strong> (+59d/yr banked).
<a href="https://www.levlhealth.com/LEVTrajectory/" target="_blank" rel="noopener noreferrer" style="color: #047857; font-weight: 700; margin-left: 6px;">Calculate your LEV Trajectory →</a>
</td>
</tr>
</table>